
STAAR Surgical Company
STAA
Updated: 23/09/2026, 19:29:25
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
No summaries found.
- Share price
- $20.34
- Market cap
- $1.01B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Warren Foust
- Employees
- 921
- IPO date
- 24/02/1992
- Beta
- 1.221
- Last dividend
- $0.00
- Day range
- $20.23 – $21.00
- 52-week range
- $15.59 – $35.87
- 1-day performance
- -1.49%
- 1-year performance
- 30.49%
- Current drawdown (1Y)
- -43.29%
- CIK
- 0000718937
- CUSIP
- 852312305
- ISIN
- US8523123052
- Created
- 07/12/2025, 14:23:49
- Last update
- 23/09/2026, 19:29:25
Track STAAR Surgical Company with an AI analyst
See which prediction-market events move STAA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
Seeking Alpha • STOCK • 28/05/2026, 03:20:15
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Seeking Alpha • STOCK • 16/05/2026, 12:10:39
Staar Surgical (NASDAQ: STAA) Soars: Price Target Hike and Strong Financial Rebound
Market Data • Market Data • 14/05/2026, 14:15:52
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 14/05/2026, 03:20:43
STAAR Surgical Q1 Earnings Call Highlights
MarketBeat • STOCK • 14/05/2026, 02:14:26
Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 13/05/2026, 20:30:19
Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research • STOCK • 13/05/2026, 20:15:56
STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
Business Wire • STOCK • 04/05/2026, 18:01:00
Surging Earnings Estimates Signal Upside for Staar Surgical (STAA) Stock
Zacks Investment Research • STOCK • 06/04/2026, 15:21:07
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 04/03/2026, 02:12:15
Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates
Zacks Investment Research • STOCK • 03/03/2026, 19:15:35
STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years
Zacks Investment Research • STOCK • 19/02/2026, 14:11:08